The global clinical diagnostics space is poised for strong growth, driven by increased adoption of advanced diagnostics technologies, greater investment in laboratories, and improved access to molecular and immunodiagnostic testing facilities. In 2025, the industry continued its transformation, establishing testing systems as intelligent systems that can operate together across different locations, as their testing value now depends on their ability to improve clinical decisions and work processes. The rise of oncology, chronic diseases, and infectious disease challenges demonstrates that while centralized laboratories can offer large-scale testing solutions, the most significant industry changes are driven by decentralized molecular testing systems, AI-based tissue analysis, and combined chemistry-immunoassay testing systems. Amid this scenario, vendors providing comprehensive testing solutions through automated and data management systems to customers seeking end-to-end testing that connects their information to reduce testing costs and support accurate medical treatment decisions are outperforming traditional testing equipment and reagent manufacturers. This analysis provides a global overview of the clinical diagnostics industry. The geographic scope includes five regions: North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa.

• What is the growth potential of centralized testing sectors like clinical chemistry and immunoassays (CC&IA), hematology, hemostasis, and molecular diagnostics?
• How are referral & peripheral testing segments like tissue diagnostics and clinical microbiology poised for exponential growth?
• Which growth avenues will redefine the decentralized testing segment and sub-segments like point-of-care testing (POCT) and self-monitoring blood glucose (SMBG)?